title: [Atypical antipsychotic-induced weight gain].
abstract: Introduction of a new group of antipsychotic drugs, called atypical because of the proprieties differing them from classical neuroleptics, gave hope for the beginning of a new era in treatment of psychoses, including schizophrenia. Different mechanisms of action not only resulted in a broader spectrum of action and high efficacy but also in a relative lack of extrapiramidal symptoms. However, atypical neuroleptics are not totally free from adverse effects. Symptoms such as sedation, metabolic changes and weight gain, often very quick and severe - present also in the case of classical drugs, but put to the background by extrapiramidal symptoms--have become prominent. Weight gain is important both from the clinical and subjective point of view--as associated with serious somatic consequences and as a source of enormous mental distress. These problems are addressed in this review, with the focus on weight gain associated with the use of specific atypical neuroleptics.
authors.affiliation: Klinika Chorób Psychicznych i Zaburzeń Nerwicowych AM w Gdańisku.
authors.forename: Beata R
authors.initials: BR
authors.lastname: Godlewska
authors.forename: Luiza
authors.initials: L
authors.lastname: Olajossy-Hilkesberger
authors.forename: Halina
authors.initials: H
authors.lastname: Marmurowska-Michałowska
authors.forename: Marcin
authors.initials: M
authors.lastname: Olajossy
authors.forename: Jerzy
authors.initials: J
authors.lastname: Landowski
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004703:Endocrine System / Q000187:drug effects; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D009765:Obesity / Q000139:chemically induced*; D011618:Psychotic Disorders / Q000188:drug therapy; D012044:Regression Analysis; D012107:Research Design; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents